DOTAREM SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

GADOTERATE MEGLUMINE

から入手可能:

GUERBET

ATCコード:

V08CA02

INN（国際名）:

GADOTERIC ACID

投薬量:

376.9MG

医薬品形態:

SOLUTION

構図:

GADOTERATE MEGLUMINE 376.9MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

VIALS:5/10/15/20/60100ML

処方タイプ:

Ethical

治療領域:

OTHER DIAGNOSTIC AGENTS

製品概要:

Active ingredient group (AIG) number: 0158590001; AHFS:

認証ステータス:

APPROVED

承認日:

2016-11-25

製品の特徴

_Product Monograph _
_DOTAREM Gadoterate meglumine injection _
_Page 1 of 42 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
DOTAREM
Gadoterate Meglumine Injection
Solution, 376.9 mg/mL, equivalent to 0.5 mmol/mL, Intravenous
Contrast Enhancement Agent for Magnetic Resonance Imaging (MRI)
Manufacturer:
Guerbet
BP 57400
95943 Roissy CdG Cedex
FRANCE
Importer:
Methapharm Inc.
81 Sinclair Blvd
Brantford, Ontario
Canada N3S 7X6
Date of Initial Authorization:
NOV 25, 2016
Date of Revision:
July 5, 2023
Submission Control Number: 269429
_ _
_Product Monograph _
_DOTAREM Gadoterate meglumine injection _
_Page 2 of 42 _
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions, 7.1.1 Pregnant Women
07/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................... 5
4
DOSAGE AND ADMINISTRATION
................................................................................
5
4.1
Dosing Considerations
...........................................................................................
5
4.2
Recommended Dose an